RITA Medical Systems Announces Second Quarter 2006 Earnings Release Date and Conference Call
2006年7月20日 - 8:30PM
PRニュース・ワイアー (英語)
FREMONT, Calif., July 20 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA) today announced that it will release
financial results for the second quarter ended June 30, 2006, after
the market close on Tuesday, August 8, 2006. The Company will also
host a conference call and live audio webcast on Tuesday, August 8,
2006 at 2:00 p.m. Pacific Time to discuss the Company's second
quarter results, outlook for the remainder of 2006, and current
corporate developments. The dial-in number for the conference call
is 800-257-1836 for domestic participants and 303-205-0066 for
international participants. A live audio webcast of the conference
call will also be available at http://www.ritamedical.com/. A taped
replay of the conference call will be available beginning
approximately one hour after the call's conclusion and will remain
available for 7 days. It can be accessed by dialing 800-405-2236
for domestic callers and 303-590-3000 for international callers,
both using the passcode 11066571#. An online replay of the audio
webcast will be available immediately following the broadcast at
http://www.ritamedical.com/. Webcast participants are encouraged to
go to the site at least 15 minutes prior to the start of the call
to register, download and install any necessary audio software.
About RITA Medical Systems, Inc. RITA Medical Systems develops,
manufactures and markets innovative products for cancer patients
including radiofrequency ablation (RFA) systems for treating
cancerous tumors as well as percutaneous vascular and spinal access
systems. The Company distributes the LC Bead(TM) (Biocompatibles,
UK) product which is used in arterial embolization of hypervascular
tumors and arteriovenous malformations and has U.S. Food and Drug
Administration (FDA) marketing clearance in the U.S. The Company's
oncology product lines include implantable ports, some of which
feature its proprietary Vortex(R) technology; tunneled central
venous catheters; and safety infusion sets and peripherally
inserted central catheters used primarily in cancer treatment
protocols. The product line also includes the HABIB 4X resection
device which coagulates a surgical resection plane and is designed
to facilitate a fast dissection in order to minimize blood loss and
blood transfusion during surgery. The proprietary RITA RFA system
uses radiofrequency energy to heat tissue to a high enough
temperature to ablate it or cause cell death. In March 2000, RITA
became the first RFA Company to receive specific FDA clearance for
unresectable liver lesions in addition to its previous general FDA
clearance for the ablation of soft tissue. In October 2002, RITA
again became the first company to receive specific FDA clearance,
this time for the palliation of pain associated with metastatic
lesions involving bone. The RITA Medical Systems website is at
http://www.ritamedical.com/. The Company cautions the reader that
the planned appearances of Company personnel, time and/or manner of
the live teleconference, webcast and replays may change for
administrative or other reasons outside the Company's control.
DATASOURCE: RITA Medical Systems, Inc. CONTACT: Stephen Pedroff, VP
Marketing Communications of RITA Medical Systems, Inc.,
+1-510-771-0400, or ; or media, Steve DiMattia, +1-646-277-8706, or
, or investors, Doug Sherk, +1-415-896-6820, or , or Jennifer
Beugelmans, +1-415-896-6820, all of EVC Group, for RITA Medical
Systems, Inc. Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 5 2024 まで 6 2024
Rita Medical (NASDAQ:RITA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Rita Medical Systems (ナスダック市場): 0 recent articles
その他のRita Medical Systems (MM)ニュース記事